Drugs / APVO101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03855280 | Jan 2020 → Jul 2022 | hemophilia B | Medexus Pharma, Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APVO101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03855280 ↗ |
| Action | Restore | “factor IX replacement therapy” NCT03855280 ↗ |
| Modality | Protein / enzyme biologic | “Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B” NCT03855280 ↗ |
| Route | Intravenous | “Subjects will receive a single IV dose of APVO101 twice weekly or at a frequency of infusions as determined appropriate by the investigator for the particular study subject for...” NCT03855280 ↗ |